Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic Focal Segmental Glomerulosclerosis: A Prospective Study of Acthar (PODOCYTE)

CompletadoFase 4ClinicalTrials.gov

ID: NCT02633046Tipo: INTERVENTIONALInicio: 10 de oct de 2016Fin estimado: 27 de ago de 2020

Traducción no disponible, mostrando original

Resumen

Focal segmental glomerulosclerosis (FSGS) is a condition that harms the kidney "filters" that remove waste from the blood. Proteins are supposed to stay in the blood. Damaged "filters" let protein get into the kidney. FSGS is a serious condition that can lead to kidney failure. The only treatment for kidney failure is dialysis or kidney transplant. Proteinuria means too much protein came through the kidneys into the urine. If the doctor cannot figure out what is causing the problem, it is primary (idiopathic) FSGS. This kind of FSGS is very hard to treat. This study will test Acthar in patients with this condition who have not responded to other treatments. It primarily investigates how well the therapy is tolerated by the patients and how well they respond to this treatment.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Potential participants must meet the following summary criteria for inclusion in the study:
Is male or non-pregnant, non-lactating female
Has primary FSGS, is nephrotic and did not achieve at least partial proteinuria response with prior therapy
Has been treated with an angiotensin converting enzyme inhibitor or receptor blocker (or have documented intolerance), for at least 4 weeks before screening
Has blood pressure no higher than 150/90 mmHg

Criterios de exclusión

Potential participants will not be eligible for the the study if they meet the following summary criteria:
Has hepatitis B or C, tuberculosis, or other contraindication listed on the United States (US) Prescribing Information for Acthar
Has Type 1 or Type 2 diabetes mellitus or any clinically significant infection
Has received specific treatments at exclusionary time points per protocol
Has been involved in a therapeutic drug/device trial (other than for FSGS) within 4 weeks before screening
Has any other condition that might, per protocol or in the opinion of the investigator, compromise:
the safety and well-being of the participant or their offspring
the safety of study staff
analysis of results

Intervenciones

drug

Acthar Gel

Acthar Gel 80 U/mL solution for subcutaneous injection

Ubicaciones

Centro de Salud Renal Junín SRL

Junín, Buenos Aires, Argentina

Centro de Investigaciones Médicas

Mar del Plata, Buenos Aires, Argentina

Sanatorio Allende

Córdoba, Argentina

Patrocinadores

PrincipalMallinckrodt ARD LLC

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

Treatment of Proteinuria Due to Treatment Resistant or Tr... | EligiMed